US Tariffs on Patented Pharma Imports Hit Global Supply

US tariffs on patented pharma imports are set to reshape global drug trade, with India facing a mixed impact as the policy targets high-value medicines while sparing generics for now.

The US tariffs on patented pharma imports impose duties of up to 100 percent on branded drugs entering the United States.

The move is aimed at pushing global pharmaceutical companies to lower prices for American consumers and shift manufacturing operations to the US. Companies that fail to comply with pricing expectations or domestic production goals may face the full tariff burden.

For India, the immediate impact appears limited. The country’s pharma exports to the US are heavily dominated by generic drugs, which remain exempt from these tariffs. This offers short-term relief to Indian drugmakers that rely on volume-driven exports of affordable medicines.

Also Read: The Future of MedTech in India: Meeting Tier-2 and Tier-3 Needs

However, the long-term outlook is less certain. The tariffs also affect active pharmaceutical ingredients and patented drug segments, where India plays a key role in global supply chains. As multinational pharma companies reconsider manufacturing locations, there is a growing risk of production shifting toward the US to avoid tariff costs.

This could impact India’s contract manufacturing business and reduce future investments in high-value drug development. Indian firms expanding into specialty and patented drug markets may also face increased pricing pressure and reduced competitiveness.

The policy reflects a broader US strategy to strengthen domestic manufacturing in critical sectors like healthcare. While India’s generic drug dominance provides a buffer today, the evolving trade environment could reshape the industry’s global positioning over time.